The role of type 1 and type 2 5′-deiodinase in the pathophysiology of the 3,5,3′-triiodothyronine toxicosis of McCune-Albright syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2383-2389

  Celi, Francesco S ^a,b,c,d   Coppotelli, Giuseppe ^a,b,c,d   Chidakel, Aaron ^a,b,c,d   Kelly, Marilyn ^a,b,c,d   Brillante, Beth A ^a,b,c,d   Shawker, Thomas ^a,b,c,d   Cherman, Natasha ^a,b,c,d   Feuillan, Penelope P ^a,b,c,d   Collins, Michael T ^a,b,c,d  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' DEIODINASE 1; 5' DEIODINASE 2; COMPLEMENTARY DNA; LIOTHYRONINE; THYROXINE 5 DEIODINASE; THYROXINE DEIODINASE;

ADOLESCENT; ADULT; ALBRIGHT SYNDROME; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHYROIDISM; INTOXICATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; THYROID DISEASE; THYROID FUNCTION;

EID: 45149104942     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2237     Document Type: Article

References (37)

1. McCune DJ 1936 Osteitis fibrosa cystica: the case of a nine-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 52:743-744
2. Albright F, Butler AM, Hampton AO, Smith P 1937 Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation, and endocrine dysfunction, with precocious puberty in females: report of 5 cases. N Engl J Med 216:727-746
3. Collins MT 2004 McCune-Albright syndrome. In: Filetti S, ed. Paris: Orphanet
4. Feuillan PP 1997 McCune-Albright syndrome. Curr Ther Endocrinol Metab 6:235-239
5. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
6. Schwindinger WF, Francomano CA, Levine MA 1992 Identification of a mutation in the gene encoding the α subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152-5156
7. Lumbroso S, Paris F, Sultan C 2004 Activating Gsα mutations: analysis of 113 patients with signs of McCune-Albright syndrome - a European Collaborative Study. J Clin Endocrinol Metab 89:2107-2113
8. Collins MT, Shenker A 1999 McCune-Albright syndrome: new insights. Curr Opin Endocrinol Diabetes 6:119-125
9. Feuillan PP, Shawker T, Rose SR, Jones J, Jeevanram RK, Nisula BC 1990 Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormonal studies. J Clin Endocrinol Metab 71:1596-1601
10. Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA 1997 Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 7:433-439
11. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A 2003 Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs α mutations. J Clin Endocrinol Metab 88:4413-4417
12. Michiels FM, Caillou B, Talbot M, Dessarps-Freichey F, Maunoury MT, Schlumberger M, Mercken L, Monier R, Feunteun J 1994 Oncogenic potential of guanine nucleotide stimulatory factor α subunit in thyroid glands of transgenic mice. Proc Natl Acad Sci USA 91:10488-10492
13. Salvatore D, Tu H, Harney JW, Larsen PR 1996 Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest 98:962-968
14. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, Mizuma H, Mori M 2001 Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142:2961-2967
15. Brtko J, Bobalova J, Podoba J, Schmutzler C, Kohrle J 2002 Thyroid hormone receptors and type I iodothyronine 5′-deiodinase activity of human thyroid toxic adenomas and benign cold nodules. Exp Clin Endocrinol Diabetes 110:166-170
16. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89
17. Weetman AP, Shepherdley CA, Mansell P, Ubhi CS, Visser TJ 2003 Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. Eur J Endocrinol 149:443-447
18. Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey PG 2000 Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 15:120-128
19. Amino N, Yabu Y, Miyai K, Fujie T, Azukizawa M, Onishi T, Kumahara Y 1978 Differentiation of thyrotoxicosis induced by thyroid destruction from Graves' disease. Lancet 2:344-346
20. Coppotelli G, Summers A, Chidakel A, Ross JM, Celi FS 2006 Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5′ UTR of the gene. Thyroid 16:625-632
21. St. Germain DL 1988 Dual mechanisms of regulation of type I iodothyronine 5′-deiodinase in the rat kidney, liver, and thyroid gland. Implications for the treatment of hyperthyroidism with radiographic contrast agents. J Clin Invest 81:1476-1484
22. Ringel MD, Schwindinger WF, Levine MA 1996 Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 75:171-184
23. Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR, Weetman AP 2003 Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab 88:594-598
24. Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K, Pedersen KM 2007 Sources of circulating 3,5,3′- triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 92:2149-2156
25. Laurberg P 1986 Thyroxine entering the thyroid gland via the vascular bed may leave the gland as triiodothyronines. Studies with perfused dog thyroid lobes. Endocrinology 118:895-900
26. 3 in euthyroid humans. J Clin Invest 115:2524-2533
27. Collins MT 2006 Spectrum and natural history of fibrous dysplasia of bone. J Bone Miner Res 21(Suppl 2):P99-P104
28. Jakobs TC, Schmutzler C, Meissner J, Kohrle J 1997 The promoter of the human type I 5′-deiodinase gene - mapping of the transcription start site and identification of a DR+4 thyroid-hormone-responsive element. Eur J Biochem 247:288-297
29. Curcio-Morelli C, Zavacki AM, Christofollete M, Gereben B, de Freitas BC, Harney JW, Li Z, Wu G, Bianco AC 2003 Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. J Clin Invest 112:189-196
30. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeold A, Capelo LP, Curcio-Morelli C, Ribeiro R, Harney JW, Tabin CJ, Bianco AC 2005 The Hedgehoginducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 7:698-705
31. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR 2000 Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′- monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology 141:229-237
32. Canettieri G, Celi FS, Baccheschi G, Salvatori L, Andreoli M, Centanni M 2000 Isolation of human type 2 deiodinase gene promoter and characterization of a functional cyclic adenosine monophosphate response element. Endocrinology 141:1804-1813
33. Kim BW, Zavacki AM, Curcio-Morelli C, Dentice M, Harney JW, Larsen PR, Bianco AC 2003 Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl region of D2. Mol Endocrinol 17:2603-2612
34. Gereben B, Salvatore D 2005 Pretranslational regulation of type 2 deiodinase. Thyroid 15:855-864
35. Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM 1999 Special features of Graves' disease in early childhood. Thyroid 9:871-877
36. Leonard JL, Rosenberg IN 1978 Thyroxine 5′-deiodinase activity of rat kidney: observations on activation by thiols and inhibition by propylthiouracil. Endocrinology 103:2137-2144
37. Visser TJ, Kaplan MM, Leonard JL, Larsen PR 1983 Evidence for two pathways of iodothyronine 5′-deiodination in rat pituitary that differ in kinetics, propylthiouracil sensitivity, and response to hypothyroidism. J Clin Invest 71:992-1002